3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Pancreatic Neoplasms
57
Carcinoma, Non-Small-Cell Lung
30
Breast Neoplasms
26
Neoplasms
24
Neoplasm Metastasis
24
Triple Negative Breast Neoplasms
21
Parkinson Disease 4, Autosomal Dominant Lewy Body
10
Lung Neoplasms
9
Melanoma
8
Stomach Neoplasms
7
Carcinoma, Pancreatic Ductal
7
Adenocarcinoma
7
Ovarian Neoplasms
6
Colorectal Neoplasms
6
Squamous Cell Carcinoma of Head and Neck
4
Esophageal Neoplasms
4
Digestive System Neoplasms
4
Uterine Cervical Neoplasms
3
Urinary Bladder Neoplasms
3
Small Cell Lung Carcinoma
3
Sarcoma
3
Recurrence
3
Rectal Neoplasms
3
Pancreatic Diseases
3
Neoplasms by Site
3
Lymphoma, Non-Hodgkin
3
Fallopian Tube Neoplasms
3
Endometrial Neoplasms
3
Endocrine Gland Neoplasms
3
Digestive System Diseases
3
Interventions
seribantumab
2
Gemcitabine
2
Docetaxel
2
130-nm albumin-bound paclitaxel
2
patritumab
1
Istiratumab
1
Albumin-Bound Paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Fibromatosis, Gingival, 2
×
Albumin-Bound Paclitaxel
×
Clear all
NCT02399137
2018-09-18
CARRIE
Merrimack Pharmaceuticals
Phase 2
Completed
88 enrolled